Imogen Fitteditorial@labpulse.comHomeWhy best-of-breed LIS vendors might yet survive EHR’s invasionIs EHR-based LIS therefore a foregone conclusion? Or is there a place still for dedicated BoB-LIS? Based on our latest research assessing the global LIS market, the evidence points to a surprisingly bright future for BoB-LIS.May 30, 2022Pathology, histologyDigital pathology: What does the future hold?There are unique circumstances causing this, including a combination of overregulation, tight reimbursement, and a lack of evidence for tangible cost savings. However, even despite this, pathology's dwindling workforce and increasing caseloads have always made the case for digitization's seeming inevitability.Table 1: Digital pathology drivers and barriers. 1= Least important, 10 = Most important.Table 1: Digital pathology drivers and barriers. 1= Least important, 10 = Most important.December 20, 2021Artificial IntelligenceVenture capital funding for digital pathology tops $860MInvestment is now evolving to focus on startups developing artificial intelligence (AI) solutions for digital pathology image analysis.Image courtesy of Signify.Image courtesy of SignifyApril 26, 2021Page 1 of 1Top StoriesCancerInvivoscribe, Complete Genomics partner to develop NGS tests for cancer research, detectionUnder the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software. The tests will run on Complete Genomics' NGS platforms.Regulatory ApprovalSeegene obtains IVDR certification for 30 diagnostic assaysPolicy and RegulationAdvocacy groups in letter urge FDA to develop regulations for lab-developed testsCollaborationNucleai, Adlai Nortye collaborate on biomarkers for clinical trialsSponsor ContentVisit our Molecular Diagnostics Community
